Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Fumiyoshi Ohyanagi

First-In-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients With Advanced Solid Tumors

Molecular Cancer Therapeutics
Cancer ResearchOncology
2019English

Rapid Progression of Lung Cancer Following Emergency Caesarean Section Led to Postpartum Acute Respiratory Failure

Internal Medicine
Internal MedicineMedicine
2019English

Related publications

First-In-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients With Advanced Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2013English

First‐in‐human Phase I Study of E7090, a Novel Selective FGFR Inhibitor, in Patients With Advanced Solid Tumors

Cancer Science
Cancer ResearchMedicineOncology
2020English

First-In-Human Phase I Study of Lurbinectedin (PM01183) in Patients With Advanced Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2014English

Erratum To: First-In-Human Phase I Study of SOR-C13, a TRPV6 Calcium Channel Inhibitor, in Patients With Advanced Solid Tumors

Investigational New Drugs
OncologyPharmacology
2017English

Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora a Kinase Inhibitor, in Patients With Advanced Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2012English

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2013English

Phase I Study of TAS-102 Treatment in Japanese Patients With Advanced Solid Tumours

British Journal of Cancer
Cancer ResearchOncology
2012English

A Phase I Study of BI 811283, an Aurora B Kinase Inhibitor, in Patients With Advanced Solid Tumors

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2016English

Correction: Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy